Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

ABSTRACT: The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression. However, these reports have not penetrated the community, and many patients do not receive appropriate therapy. Additionally, several immune checkpoint inhibitors have recently been approved for treatment of metastatic disease. The approval of immune checkpoint blockade for p

SUBMITTER: Kamat AM 

PROVIDER: S-EPMC5557323 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature